Evidence map›Paper›PMID 42884140›Full record

ArticleInternational journal of molecular sciences2026

CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant.

Elena Kondratyeva, Anna Efremova, Yuliya Melyanovskaya, Elena Zhekaite, Maria Sapelnikova, Michael Milovanov, Olga Shchagina, Anna Voronkova, Victoria Sherman, Stanislav Krasovsky and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elena KondratyevaResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.ORCID 0000-0001-6395-0407
Anna EfremovaResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.
Yuliya MelyanovskayaResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.ORCID 0000-0002-8814-5532
Elena ZhekaiteResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.
Maria SapelnikovaResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.
Michael MilovanovResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.
Olga ShchaginaResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.ORCID 0000-0003-4905-1303
Anna VoronkovaResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.
Victoria ShermanIndependent Researcher, Moscow 121108, Russia.
Stanislav KrasovskyResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.
Sergey KutsevResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.
Dmitry GoldshteinResearch Centre for Medical Genetics,1 Moskvorechye St., 115552 Moscow, Russia.

Funding

Russian Science Foundation No. 22-15-00473-П
6 · The paper itself

Abstract

The clinical response to elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis carrying the rare cystic fibrosis transmembrane conductance regulator (CFTR) variant W1282R has not been well characterized. We retrospectively analyzed 12 people with cystic fibrosis treated with ETI for 3-36 months in addition to ongoing standard CF therapy. Baseline lung function was generally preserved in patients with available spirometry (median percent predicted forced expiratory volume in 1 s (ppFEV

Indexed as

AminophenolsBenzodioxolesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorIndolesPyrazolesPyridinesPyrrolesPyrrolidinesQuinolonesAdolescentAdultDrug CombinationsFemaleHumansMaleAminophenolsBenzodioxolesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorDrug Combinationselexacaftorelexacaftor, ivacaftor, tezacaftor drug combinationIndolesivacaftorPyrazolesPyridinesPyrrolesPyrrolidinesQuinolinesQuinolonestezacaftorCFTRCFTR modulatorscystic fibrosiselexacaftor/tezacaftor/ivacaftorforskolin-induced swellingintestinal current measurementintestinal organoidsW1282R

Identifiers

PMID42884140
PMCPMC13665084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.